Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 5/20 | 0.45 |
| ▸ | PPARA | Q07869 | 5/20 | 0.45 |
| ▸ | APP | P05067 | 5/20 | 0.44 |
| ▸ | SLC16A3 | O15427 | 3/20 | 0.43 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.43 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883026 | 0.83 | SLC16A3 (0.55) | PPARGPPARASLC16A3SLC16A1MCTS1 | |
| SCHEMBL2716903 | 0.83 | CYP3A4 (0.44) | RXRARXRBAPPCYP3A4IDO1 | |
| SCHEMBL8935661 | 0.82 | SLC16A3 (0.46) | PPARGPPARASLC16A3SLC16A1MCTS1 | |
| SCHEMBL2215266 | 0.82 | RXRA (0.46) | RXRARXRBPPARGPPARASLC16A3 | |
| SCHEMBL31377393 | 0.81 | NPC1 (0.53) | PPARGPPARASLC16A3SLC16A1MCTS1 | |
| SCHEMBL2221138 | 0.81 | SLC16A3 (0.53) | PPARGSLC16A3SLC16A1MCTS1IDO1 | |
| SCHEMBL8935846 | 0.79 | PPARA (0.50) | PPARGPPARAIDO1PPARD | |
| Clobuzarit SCHEMBL187456 | 0.78 | SLC16A3 (0.62) | PPARGPPARASLC16A3SLC16A1MCTS1 | |
| SCHEMBL11734564 | 0.78 | PPARG (0.72) | RXRARXRBPPARGPPARAAPP | |
| SCHEMBL11957480 | 0.77 | CYP3A4 (0.52) | APPCYP3A4IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1647546-B1 | NOVEL HETEROARYL DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2012-05-02 | — | — | EP | disclosed |
| EP-1647546-B1 | NOVEL HETEROARYL DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20110212892-A1 | AGENT FOR TREATMENT OF DIABETES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110212892-A1 | AGENT FOR TREATMENT OF DIABETES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110212892-A1 | AGENT FOR TREATMENT OF DIABETES | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2351563-A1 | AGENT FOR TREATMENT OF DIABETES | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-08-03 | — | — | EP | disclosed |
| EP-2351563-A1 | AGENT FOR TREATMENT OF DIABETES | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20100286144-A1 | HETEROARYL DERIVATIVES | TAKAHASHI YOKO | 2010-11-11 | — | — | US | disclosed |
| US-20100286144-A1 | HETEROARYL DERIVATIVES | TAKAHASHI YOKO | 2010-11-11 | — | — | US | disclosed |
| US-20100286144-A1 | HETEROARYL DERIVATIVES | TAKAHASHI YOKO | 2010-11-11 | — | — | US | disclosed |
| US-20080306275-A1 | NOVEL HETEROARYL DERIVATIVE | DANIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-7425642-B2 | Heteroaryl derivative | DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7425642-B2 | Heteroaryl derivative | DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7425642-B2 | Heteroaryl derivative | DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1837329-A1 | NOVEL HETEROARYL DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-26 | — | — | EP | disclosed |
| US-20060194857-A1 | Novel heteroaryl derivative | DAINIPPON SUMITOMO PHARMA CO. LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1647546-A1 | NOVEL HETEROARYL DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212892-A1 | AGENT FOR TREATMENT OF DIABETES | SLC5A1, GLP1R, SLC5A2 | RXRA 1671/4885RXRB 2084/4885PPARG 62/4885 |
| US-20060194857-A1 | Novel heteroaryl derivative | NR0B1, UGT1A10, NR0B2 | RXRA 307/4885RXRB 262/4885PPARG 282/4885 |
| US-20100286144-A1 | HETEROARYL DERIVATIVES | GPR119, SLC2A1, SLC2A4 | RXRA 630/4885RXRB 736/4885PPARG 430/4885 |
| US-20080167306-A1 | Novel Heteroaryl Derivative | GPR119, SLC2A4, SLC5A2 | RXRA 818/4885RXRB 935/4885PPARG 498/4885 |
| US-20080306275-A1 | NOVEL HETEROARYL DERIVATIVE | NR0B1, UGT1A10, NR0B2 | RXRA 307/4885RXRB 262/4885PPARG 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.